iCAD, Inc. (ICAD)
| Market Cap | 348.58M |
| Revenue (ttm) | 28.63M |
| Net Income (ttm) | -19.36M |
| Shares Out | 23.17M |
| EPS (ttm) | -0.91 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | January 22 |
| Last Price | $15.16 |
| Previous Close | $15.03 |
| Change ($) | 0.13 |
| Change (%) | 0.86% |
| Day's Open | 15.06 |
| Day's Range | 14.10 - 15.25 |
| Day's Volume | 202,890 |
| 52-Week Range | 6.63 - 15.25 |
NASHUA, N.H., Jan. 19, 2021 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced that ...
New ProFound AI risk software, offering a 2-year projected risk score to be featured New ProFound AI risk software, offering a 2-year projected risk score to be featured
International Multi-Center Study to Commence January 2021
Agreement Positions Both Companies for Growth; Leading-edge AI Technology to be Installed Across Largest Independent Provider of Mammography and Breast Health Services' Network Agreement Posit...
Groundbreaking ProFound AI Risk Helps Transform Breast Cancer Screening from an Age-Based Paradigm to Risk-Adapted Precision Screening, Individualized for Each Woman Groundbreaking ProFound AI...
Growing Body of Evidence Supports Xoft Platform Across Multiple Cancer Types Growing Body of Evidence Supports Xoft Platform Across Multiple Cancer Types
Significant Percentage of Licenses Sold to Facilities with GE, Siemens, and Sites with Multiple Vendors Including Hologic and Fuji
iCAD, Inc. (ICAD) CEO Michael Klein on Q3 2020 Results - Earnings Call Transcript
Achieved Sequential Revenue Growth of 28% in Third Quarter of 2020, Driven by Detection Product and Therapy Product Revenue Growth of 44% and 251%, Respectively
NASHUA, N.H., Oct. 29, 2020 (GLOBE NEWSWIRE) -- iCAD , Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced tha...
iCAD Showcasing Expanded Xoft Platform Including Single-Fraction IORT Solution for Brain and Early-Stage Breast Cancer Tumors iCAD Showcasing Expanded Xoft Platform Including Single-Fraction I...
Contract with market-leading enterprise imaging provider expands access to ProFound AI for hospitals and imaging centers across North America Contract with market-leading enterprise imaging pr...
New, Encouraging Results and Overall Patient Survival Numbers to be Presented at European Congress of Neurosurgery New, Encouraging Results and Overall Patient Survival Numbers to be Presented...
Webinar Taking Place on Wednesday, October 21st @ 10amET Webinar Taking Place on Wednesday, October 21st @ 10amET
IORT reimbursement unchanged; payment values for alternative, longer courses of radiation therapy reduced IORT reimbursement unchanged; payment values for alternative, longer courses of radiat...
NASHUA, N.H., Sept. 18, 2020 (GLOBE NEWSWIRE) -- iCAD , Inc . (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today provided ...
Leading experts in multiple disciplines to share best practices on leveraging AI in clinical settings Leading experts in multiple disciplines to share best practices on leveraging AI in clinic...
NASHUA, N.H., Aug. 27, 2020 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced t...
NASHUA, N.H., Aug. 10, 2020 (GLOBE NEWSWIRE) -- iCAD , Inc . (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced ...
iCAD, Inc. (ICAD) CEO Michael Klein on Q2 2020 Results - Earnings Call Transcript
Launched ProFound AI™ Risk Offering After Receiving CE Mark in Europe
NASHUA, N.H., July 28, 2020 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced t...
First and only commercially available clinical decision support tool provides accurate two-year breast cancer risk estimation personalized for each woman
Leading-edge artificial intelligence (AI) software allows patients to receive “real time” essential breast screening amidst pandemic Leading-edge artificial intelligence (AI) software allows p...
NASHUA, N.H., June 29, 2020 (GLOBE NEWSWIRE) -- iCAD , Inc . (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced ...
NASHUA, N.H., April 23, 2020 (GLOBE NEWSWIRE) -- iCAD, Inc. (“iCAD”) (Nasdaq: ICAD) today announced it has entered into definitive agreements with several institutional investors for the pur...
Educational awareness forum to feature leading experts in discussions on risk adaptive tools and pragmatic solutions to enhance patient care during COVID-19 pandemic
NASHUA, N.H., March 31, 2020 (GLOBE NEWSWIRE) -- iCAD , Inc . (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced...
iCAD, Inc. (ICAD) CEO Michael Klein on Q4 2019 Results - Earnings Call Transcript
iCAD’s cancer detection and therapy technologies to be exhibited together for the first time in the Middle East, including the world’s first commercial deep-learning digital breast tomosynthes...
World’s first and largest open AI Marketplace expands access to ProFound AI for U.S. radiologists, 80 percent of whom use Nuance’s radiology reporting system World’s first and largest open AI ...
Company Unveils New Initiative, ProFound AI Powered by Panorama, which will Enable Breast Imaging Intelligence Technology to Correlate Findings Over Time Company Unveils New Initiative, ProFou...
ICAD, Inc. (ICAD) CEO Michael Klein on Q3 2019 Results - Earnings Call Transcript
Continued strong momentum for ProFound AI™ iCAD’s proprietary cancer detection AI technology
iCAD to Showcase Entire ProFound AI Platform, including its Solutions for 2D Mammography and Digital Breast Tomosynthesis in Paris at Medical Conference iCAD to Showcase Entire ProFound AI Pla...
iCAD présentera la plateforme complète ProFound AI, comprenant ses solutions pour la mammographie 2D et pour la tomosynthèse mammaire numérique, lors du Congrès de Radiologie à Paris iCAD prés...
Company to exhibit ProFound AI for 2D and 3D Mammography in Europe Company to exhibit ProFound AI for 2D and 3D Mammography in Europe
Enhanced x-ray source technology and full suite of Xoft eBx applicators to be showcased, including those for emerging applications in prostate, brain, and rectal cancers Enhanced x-ray source ...
First and Only FDA-Cleared Digital Breast Tomosynthesis Software with Artificial Intelligence Clinically Proven to Enhance Breast Cancer Screening, Reduce False Positives and Slash Reading Tim...
First and Only FDA-Cleared Artificial Intelligence Solution Supporting Breast Cancer Detection in 3D Tomosynthesis Recognized by Annual Awards Program First and Only FDA-Cleared Artificial Int...
iCAD's (ICAD) CEO Michael Klein on Q2 2019 Results - Earnings Call Transcript
iCAD's (ICAD) CEO Michael Klein on Q1 2019 Results - Earnings Call Transcript
iCAD, Inc. (ICAD) CEO Michael Klein on Q4 2018 Results - Earnings Call Transcript
About ICAD
iCAD provides image analysis, workflow solutions, and radiation therapy for the treatment of cancer in the United States. It operates through two segments, Cancer Detection and Cancer Therapy. The company offers PowerLook platform, which hosts the AI algorithm solutions and manages the communications between imaging acquisition systems, and image storage and review systems; SecondLook, a machine learning-based cancer detection algorithm that analyzes 2D full-field digital mammography images to identify and mark suspicious masses and calcificati... [Read more...]
| Industry Health Information Services | IPO Date Dec 3, 1986 |
| CEO Michael S. Klein | Employees 135 |
| Stock Exchange NASDAQ | Ticker Symbol ICAD |
Financial Performance
In 2019, iCAD, Inc.'s revenue was $31.34 million, an increase of 22.32% compared to the previous year's $25.62 million. Losses were -$13.55 million, 50.3% more than in 2018.
Analyst Forecasts
According to 6 analysts, the average rating for iCAD, Inc. stock is "Buy." The 12-month stock price forecast is 15.92, which is an increase of 5.01% from the latest price.